JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1200
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1150 to $1200.
August 02, 2024 | 8:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Chris Schott maintains an Overweight rating on Regeneron Pharmaceuticals and raises the price target from $1150 to $1200.
The raised price target and maintained Overweight rating from a reputable analyst at JP Morgan is likely to positively impact Regeneron's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100